Arbutus Biopharma (ABUS) News Today $3.21 +0.08 (+2.56%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABUS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Acquired by Saba Capital Management L.P.Saba Capital Management L.P. lifted its stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 31.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 887,993 shares of the biopharmaceuticalMay 19 at 7:33 AM | marketbeat.comArbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal ProgressMay 18 at 6:46 AM | msn.comHudson Bay Capital Management LP Boosts Position in Arbutus Biopharma Co. (NASDAQ:ABUS)Hudson Bay Capital Management LP boosted its position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 8.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,112,500 shares of the biopharmaceutical company's stock after purchasing an additionMay 15, 2025 | marketbeat.comArbutus Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comArbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025May 10, 2025 | msn.comArbutus Biopharma (NASDAQ:ABUS) Trading Down 6% - Here's What HappenedArbutus Biopharma (NASDAQ:ABUS) Trading Down 6% - What's Next?May 7, 2025 | marketbeat.comArbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025May 7, 2025 | globenewswire.comSusquehanna Fundamental Investments LLC Buys Shares of 202,541 Arbutus Biopharma Co. (NASDAQ:ABUS)Susquehanna Fundamental Investments LLC purchased a new position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 202,541 shares of the biopharmaceutical company's stock, valued at approximaMay 5, 2025 | marketbeat.comArbutus Biopharma Co. (NASDAQ:ABUS) Shares Sold by Boothbay Fund Management LLCBoothbay Fund Management LLC cut its position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 73.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 162,277 shares of the biopharmaceutical company's sMay 3, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 1,250,000 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)Adage Capital Partners GP L.L.C. cut its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 43.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,650,941 shares of the biopharmaceutMay 1, 2025 | marketbeat.comTwo Seas Capital LP Purchases 353,568 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)Two Seas Capital LP grew its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 4.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,740,956 shares of the biopharmaceutical company's stock afterApril 27, 2025 | marketbeat.comArbutus Biopharma (ABUS) to Release Quarterly Earnings on ThursdayArbutus Biopharma (NASDAQ:ABUS) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-arbutus-biopharma-co-stock/)April 26, 2025 | marketbeat.comJPMorgan Chase & Co. Has $2.93 Million Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)JPMorgan Chase & Co. lifted its position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 900.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 896,258 shares of the biopharmaceutical company's stock after acquiring an aApril 25, 2025 | marketbeat.comBlackBarn Capital Partners LP Buys 270,971 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)BlackBarn Capital Partners LP boosted its stake in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 13.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,341,871 shares of the biopharmaceutical company's stApril 24, 2025 | marketbeat.comArbutus Biopharma Showcases Promising Hepatitis B Research at EASL CongressApril 24, 2025 | msn.comArbutus Biopharma (NASDAQ:ABUS) Trading Up 4.8% - What's Next?Arbutus Biopharma (NASDAQ:ABUS) Trading 4.8% Higher - What's Next?April 23, 2025 | marketbeat.comArbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025April 23, 2025 | globenewswire.comFranklin Resources Inc. Takes $301,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS)Franklin Resources Inc. bought a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 92,159 shares of the biopharmaceutical company's stApril 21, 2025 | marketbeat.comQuinn Opportunity Partners LLC Buys 169,747 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)Quinn Opportunity Partners LLC lifted its stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 72.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 404,879 shares of the biopharmaceutical company's stockApril 14, 2025 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Shares Down 6.3% - Here's What HappenedArbutus Biopharma (NASDAQ:ABUS) Shares Down 6.3% - Here's What HappenedApril 9, 2025 | marketbeat.comADAR1 Capital Management LLC Decreases Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)ADAR1 Capital Management LLC lowered its stake in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 25.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,554,802 shares of the biopharApril 9, 2025 | marketbeat.comRangeley Capital LLC Acquires Shares of 1,459,000 Arbutus Biopharma Co. (NASDAQ:ABUS)Rangeley Capital LLC acquired a new position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,459,000 shares of the biopharmaceuticApril 5, 2025 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.comStockNews.com upgraded Arbutus Biopharma from a "sell" rating to a "hold" rating in a report on Saturday.March 30, 2025 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Issues Quarterly Earnings ResultsArbutus Biopharma (NASDAQ:ABUS - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. The firm had revenue of $1.57 million during the quarter, compared to analyst estimates of $2.20 million.March 29, 2025 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Trading 4.1% Higher Following Strong EarningsArbutus Biopharma (NASDAQ:ABUS) Trading Up 4.1% on Strong EarningsMarch 29, 2025 | marketbeat.comChardan Capital Reaffirms "Buy" Rating for Arbutus Biopharma (NASDAQ:ABUS)Chardan Capital reaffirmed a "buy" rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Friday.March 29, 2025 | marketbeat.comArbutus Biopharma Reports 2024 Financial Results and Strategic UpdatesMarch 28, 2025 | msn.comArbutus Biopharma: A Wing And A PrayerMarch 28, 2025 | seekingalpha.comWhat is Chardan Capital's Estimate for ABUS FY2025 Earnings?Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Chardan Capital increased their FY2025 earnings per share estimates for shares of Arbutus Biopharma in a report issued on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will post earnings ofMarch 28, 2025 | marketbeat.comArbutus Biopharma reports FY24 EPS (38c), consensus (55c)March 28, 2025 | markets.businessinsider.comArbutus Biopharma reduced workforce by 57%March 28, 2025 | markets.businessinsider.comArbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec ShuffleMarch 27, 2025 | marketwatch.comArbutus announces a 57% workforce reductionMarch 27, 2025 | msn.comArbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate UpdateMarch 27, 2025 | globenewswire.comCorbin Capital Partners L.P. Sells 170,817 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)Corbin Capital Partners L.P. reduced its stake in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 20.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 682,487 shares of the biopharmaceutical company's stock after selling 17March 22, 2025 | marketbeat.comArbutus Biopharma Co. (NASDAQ:ABUS) Sees Significant Increase in Short InterestArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) saw a significant increase in short interest in February. As of February 28th, there was short interest totalling 8,410,000 shares, an increase of 16.6% from the February 13th total of 7,210,000 shares. Approximately 4.6% of the shares of the stock are short sold. Based on an average daily volume of 860,500 shares, the days-to-cover ratio is presently 9.8 days.March 20, 2025 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Trading Up 6.3% - Here's What HappenedArbutus Biopharma (NASDAQ:ABUS) Stock Price Up 6.3% - Here's What HappenedMarch 14, 2025 | marketbeat.comStockNews.com Downgrades Arbutus Biopharma (NASDAQ:ABUS) to SellStockNews.com downgraded shares of Arbutus Biopharma from a "hold" rating to a "sell" rating in a research report on Thursday.March 13, 2025 | marketbeat.comChardan Capital Has Negative Outlook of ABUS FY2025 EarningsArbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Stock analysts at Chardan Capital decreased their FY2025 earnings per share (EPS) estimates for shares of Arbutus Biopharma in a note issued to investors on Tuesday, March 4th. Chardan Capital analyst K. Nakae now anticipates that the biopharmacMarch 8, 2025 | marketbeat.comSBI Securities Co. Ltd. Makes New Investment in Arbutus Biopharma Co. (NASDAQ:ABUS)SBI Securities Co. Ltd. acquired a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 72,280 shares of the bMarch 6, 2025 | marketbeat.comGenevant and Arbutus file lawsuits against ModernaMarch 6, 2025 | uk.investing.comGenevant Sciences and Arbutus Biopharma File International Lawsuits Against Moderna for Patent Infringement of Lipid Nanoparticle TechnologyMarch 5, 2025 | nasdaq.comGenevant, Arbutus initiate patent infringement actions against ModernaMarch 4, 2025 | markets.businessinsider.comGenevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against ModernaMarch 3, 2025 | globenewswire.comGenevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against ModernaMarch 3, 2025 | globenewswire.comBrokers Issue Forecasts for ABUS FY2029 EarningsArbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Arbutus Biopharma in a report released on Wednesday, February 26th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical companyFebruary 28, 2025 | marketbeat.comArbutus Biopharma (ABUS) Projected to Post Earnings on ThursdayArbutus Biopharma (NASDAQ:ABUS) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comArbutus Biopharma's Entire Board Replaced as New CEO Steps InFebruary 25, 2025 | marketwatch.comArbutus Biopharma appoints Lindsay Androski as CEOFebruary 25, 2025 | markets.businessinsider.comArbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading Volume - Should You Buy?Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - Should You Buy?February 25, 2025 | marketbeat.com Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Media Mentions By Week ABUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABUS News Sentiment▼0.200.65▲Average Medical News Sentiment ABUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABUS Articles This Week▼53▲ABUS Articles Average Week Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XENE News AMRX News HCM News OGN News MIRM News APLS News ARWR News VCEL News NAMS News AAPG News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABUS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABUS Stock Free ABUS Stock Alerts